Experiment Proposal (crux): Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD — lncRNAs are typically intracellular effectors—exosome packaging, BBB penetration

AIMS

HYPOTHESES

PROTOCOL SUMMARY

Phase 1 - Molecular Identity & Sequence Validation: (Weeks 1-4) Request defining sequence from hypothesis proponents. If unavailable, synthesize 3 candidate sequences based on criteria: (a) length 500-2000nt, (b) predicted nuclear retention signal absent, (c) GC content 40-60%. Clone into lentiviral vector with RFP tag for tracking. Validate nuclear/cytoplasmic localization in HEK293 via fractionation RT-qPCR. Phase 2 - Exosome Packaging Efficiency: (Weeks 5-10) Transfect HEK293T with lncRNA construct. Isolate exosomes via ultrafiltration/UCF (110,000g, 2h). Perform: (a) NTA for size/concentration, (b) RT-qPCR for lncRNA cargo quantification, (c) small RNA-seq to confirm no degradation, (d)Cryo-EM for morphological integrity. Test 3 different producer cell lines (HEK293T, mesenchymal stem cells, immature dendritic cells) to identify optimal packaging efficiency. Target: ≥10^6 copies/μg protein. Phase 3 - BBB Penetration & CNS Delivery: (Weeks 11-20) Use C57BL/6 mice with established 5xFAD AD pathology (12 months old). Inject fluorophore-labeled exosomes (10^10 particles, IV tail vein). Time course: 2h, 6h, 24h, 48h. Harvest: plasma, brain (4 regions), liver, spleen. Measure: (a) exosomal lncRNA via RT-qPCR in each tissue, (b) RFP signal via fluorescence microscopy, (c) CD31+ brain endothelial co-staining to assess transcytosis. Use hCMEC/D3 cell monolayer BBB model for in vitro transcytosis assay in parallel. Phase 4 - p-tau217 Trigger Correlation: (Weeks 21-26) In separate AD mouse cohort, measure plasma p-tau217 at time of exosome injection. Correlate with CNS lncRNA delivery efficiency. Test whether pre-injection plasma p-tau217 predicts subsequent brain lncRNA accumulation. Phase 5 - Functional Validation: (Weeks 27-36) Treat primary cortical neurons from 5xFAD mice with exosomal lncRNA (10 μg/mL, 48h). Measure: (a) GSK-3β phosphorylation (Ser9, inactive form) via Western blot, (b) NF-κB p65 nuclear translocation via IF, (c) LC3-II/LC3-I ratio and p62 degradation as autophagy markers via Western blot. Include scramble lncRNA exosome control and naked lncRNA transfection as controls. Phase 6 - Therapeutic Window Analysis: (Weeks 37-44) Evaluate whether p-tau217-triggered dosing (based on correlated delivery efficiency) produces wider therapeutic window vs fixed dosing. Monitor behavioral outcomes (Y-maze, novel object recognition) and biomarker changes over 8 weeks. Controls: Empty exosomes, scrambled lncRNA exosomes, IV-administered naked lncRNA, blood-brain barrier disruption (Mannitol) positive control. Blinding maintained throughout all assessments.

PREDICTED OBSERVATIONS

If H1-3 are true: Exosomal lncRNA cargo will be detectable at ≥10^6 copies/μg, with measurable CNS parenchymal accumulation (particularly in hippocampus and cortex), co-localization with neuronal markers (NeuN+) and glial markers (Iba1+), and significant modulation of all three target pathways (decreased GSK-3β activity, reduced NF-κB nuclear translocation, increased autophagy flux). If H4 is true: High p-tau217 mice will show 2-3 fold greater CNS lncRNA delivery vs low p-tau217 mice, supporting biomarker-triggered dosing rationale. If hypotheses are false: lncRNA will be absent or degraded in exosomal preparations, CNS delivery will be below 0.001% of injected dose, and functional pathway assays will show no significant difference from scramble controls, indicating exosome packaging and BBB delivery represent insurmountable barriers for this therapeutic approach.

FALSIFICATION CRITERIA

F1: Exosome isolation yields <10^4 copies lncRNA/μg protein after testing all 3 producer cell lines → lncRNA packaging into exosomes is not feasible with current technology. F2: CNS lncRNA detection below 0.001% of injected dose at all time points despite detectable plasma levels → BBB transcytosis is blocked or negligible. F3: In vitro BBB model shows no transcytosis across hCMEC/D3 monolayers → barrier is non-permeable to exosomal lncRNA. F4: p-tau217 plasma levels show no correlation with CNS delivery efficiency (r<0.3, p>0.05) → biomarker-triggered dosing has no mechanistic basis. F5: Functional assays show no significant pathway modulation (<20% change vs control, p>0.05) → intracellular delivery insufficient for target engagement. Meeting any 3 of 5 falsification criteria constitutes sufficient evidence to reject the exosome-based lncRNA-0021 therapeutic approach as currently proposed.

DATASET DEPENDENCIES